Open-label extension for completers of earlier study
Part of Hormones & metabolism, Mental health clinical trials.
This trial is for people who finished a 12-week study (NCT06221852) and still meet its original requirements. It offers continued access to the study treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You completed the 12-week study (NCT06221852).
- You still meet the health requirements you had at the start of that study.
- You are not currently ineligible for any reason covered by the earlier study's rules.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether a special high-fat, low-carbohydrate diet (ketogenic diet) can help people who have recently been diagnosed with bipolar disorder. It may improve mood stability and overall brain health.
This study checks how safe a kid’s ongoing treatment is over a longer period. It is mainly for children who already finished a related study and may benefit from continuing the same medicines.
This trial tests an investigational drug called LB-102 for people with bipolar I disorder who are currently experiencing a major depressive episode without psychosis. It aims to see if the drug is safe and effective for treating depression symptoms.
This study tests whether a ketone drink can change how the body uses energy in people with bipolar disorder. It may help understand new ways to manage the condition.
This study follows up on people with Parkinson's disease who took part in an earlier trial testing the effects of ketamine. It looks at how they do over a longer period of time.
This study looks at how a ketogenic diet (very low carb, high fat) might affect brain function in people with bipolar disorder. Participants will follow the diet and have brain scans and blood tests to see how it helps mood and energy levels.
Hear when a new Bipolar I Disorder trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.